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ABSTRACT

In the struggle with antibiotic resistance, we are losing. There is now a
serious threat of moving into a postantibiotic world. High levels of resistance, in
terms of both frequency and strength, have evolved against all clinically approved
antibiotics worldwide. The usable life span of new clinically approved antibiotics is
typically less than a decade before resistance reaches frequencies so high as to
require only guarded usage. However, microbes have produced antibiotics for millennia without resistance becoming an existential issue. If resistance is the inevitable
consequence of antibiotic usage, as has been the human experience, why has it not
become an issue for microbes as well, especially since resistance genes are as prevalent in nature as the genes responsible for antibiotic production? Here, we ask how
antibiotics can exist given the almost ubiquitous presence of resistance genes in the
very microbes that have produced and used antibiotics since before humans walked
the planet. We ﬁnd that the context of both production and usage of antibiotics by
microbes may be key to understanding how resistance is managed over time, with
antibiotic synthesis and resistance existing in a paired relationship, much like a cipher and key, that impacts microbial community assembly. Finally, we put forward
the cohesive, ecologically based “secret society” hypothesis to explain the longevity
of antibiotics in nature.

KEYWORDS antibiotic resistance, community assembly, cooperation, evolution

WHY DO ANTIBIOTICS EXIST IN NATURE?
he majority of developed antibiotics owe their existence to microbes. Antibiotics
likely have been part of the microbial world for millions of years (1, 2). But from the
time they were discovered by humans and put into clinical use, we consistently see resistance evolve to high frequencies in short periods of time, typically within a decade
or so (Fig. 1). Resistance is often to such a high degree, in terms of frequency and level,
that the antibiotic becomes effectively useless for chemotherapeutic purposes. Given
these two very different outcomes, we must consider why antibiotic use has not led to
resistance in natural microbial usage as it so reliably has for humans.
The fact that all human use of antibiotics has led to antibiotic resistance implies
that resistance may be inevitable. This outcome is not surprising given the intense
selection for resistance in antibiotic-laden environments. But, if resistance is inevitable,
why did resistance to all naturally occurring antibiotics not evolve and eliminate the
possibility of miracle drugs long before the discovery of penicillin almost a century
ago? Do microbes just manage antibiotics better, or is there something intrinsic about
microbial use of these compounds that sustains their applicability? Why has resistance
to even the oldest forms of naturally occurring antibiotics not reached ﬁxation? Surely,
enough time has elapsed for this possibility to occur. What do microbes and humans
do differently? In short, we need to ask ourselves: why do antibiotics exist at all? Here,
we review the current state of knowledge concerning antibiotic use and effect in both
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FIG 1 Antibiotic classes, their clinical introduction, and resistance identiﬁcation. The resistance-free life spans of the
major classes of antibiotics are indicated. Years of ﬁrst clinical use (indicated by green triangles) reﬂect approval by
regulatory agencies, usually in the United States. In most cases, the discovery of the class of compounds predates
clinical approval by several years, although widespread use of the drug would not occur until approvals were secured.
The year resistance was ﬁrst reported in the literature is indicated by a red bar. In cases where resistance was reported
prior to clinical approval, the red bar precedes the green triangle, which then points toward the red resistance bar.
Cases where clinical approval was received in the same year that resistance was ﬁrst reported are indicated by a
purple circle. The antibiotic class with the longest resistance-free lifetime is polymyxin, which was not commonly used
for decades due to toxicity in humans (108).

natural and human-controlled systems to better understand the role of antibiotics in
the ecology and evolution of microbes past and present.
THE ORIGIN OF ANTIBIOTICS AND THE ANTIBIOTIC ORIGIN STORY
The cornerstone of modern medicine was laid in the 1890s when Paul Ehrlich, working with in vivo stains, developed the idea of pairing stain-like compounds capable of
entering cells with toxins that could kill it. Ehrlich’s work led to the development of salvarsan, the world’s ﬁrst antibacterial (3). Dyes continued to be a focus in the new ﬁeld
of “chemiotherapy.” In 1935, Gerhard Domagk showed that prontosil, a red dye, was
effective against streptococcal infections (4), making it the ﬁrst sulfa drug (5). Prontosil
was also highly effective against puerperal fever, most associated with deaths in
women following childbirth (6). Sulfa drugs suffered from negative side effects and
were used with limited success in the mid-twentieth century, particularly during World
War II (7).
ANTIBIOTICS
Salvarsan and prontosil were the ﬂagship drugs of the ﬁrst two classes of antimicrobial chemotherapy. But while bactericidal, they were both synthetic and not naturally
occurring biomolecules. The ﬁrst true antibiotic, penicillin, was discovered by Alexander
Fleming in 1928. Fleming’s observation that a fungus, Penicillium notatum, inhibited the
growth of staphylococci on agar medium led to the isolation and identiﬁcation of what
became known as penicillin.
Contrary to how we think of penicillin today, medicine was not revolutionized overnight, even though Fleming published his ﬁndings immediately (8). Rather, Fleming
found that cultivating the fungus was difﬁcult and that purifying penicillin was problematic. As such, what would later be called the miracle drug was not well known until
the problem of production was taken up by Ernst Boris Chain, Howard Florey, Norman
Heatley, and Edward Abraham. The work of these chemists led to the isolation and
November/December 2021 Volume 12 Issue 6 e01966-21
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puriﬁcation of penicillin along with techniques to efﬁciently prepare solutions that
could then be administered to patients (9). Another milestone in the development of
penicillin occurred when another fungal strain, Penicillium chrysogenum, which produced many times more penicillin than Fleming’s strain, was isolated from moldy fruit
by Mary Hunt at the Northern Regional Research Laboratory in Illinois (10).
Clinical use of penicillin began in 1940, but the world’s ﬁrst true antibiotic was
largely ineffective against many infectious diseases because penicillin works only
against Gram-positive bacteria (8). Treatment of Gram-negative bacteria would wait for
the next major advancement in infectious disease control, which came when streptomycin was discovered in the lab of Selman Waksman at Rutgers University in 1943 (11).
RISE OF RESISTANCE
The ﬁrst antibiotic resistance described in published reports was to penicillin, in 1940
(12). Streptomycin resistance was reported in the ﬁrst randomized controlled clinical trial
for a drug in 1948 (13). In fact, resistance to all known antibiotics (whether natural or synthetic) followed quickly after clinical or industrial use of the drug (Fig. 1). The typical
response was to identify and develop new antibiotics to replace older classes, leading to
what has been called the golden age of antibiotics in the 1950s and 1960s (14). However,
the pipeline of new, easily identiﬁed antibiotics was quickly exhausted (reviewed in reference 15), leading to a lack of available treatment options by the 1970s that continues
today. Some programs, such as the 10  ’20 initiative (16), have added newly approved
antibiotics, but this trend seems likely to be short-lived (17).
There are two major reasons for the decline in new antibiotics over the past halfcentury: greater difﬁculty in identifying new classes of drugs (18) and the skyrocketing
costs of development. The cost of bringing a new drug to market is estimated to be
over $3.12 billion (converted from 2013 dollars) (19). With such an investment required,
pharmaceutical companies have little ﬁnancial interest in developing low-proﬁt, shorttreatment-duration medicines such as antibiotics. Financial concerns are further magniﬁed given that the life expectancy of these new and expensive products has consistently been limited to less than a decade of clinical use due to antibiotic-resistant
strains rising to high frequency within that time (Fig. 1).
In reaction to the antibiotic resistance problem and with treatment options dwindling, public health ofﬁcials attempted to control antibiotic usage as a means of controlling resistance (20). The expectation was that rates of resistance would diminish as
antibiotic usage dropped. However, resistance persisted even in the face of such drug
management practices on both small and large scales (20–23). This failed approach for
controlling the evolution of resistance by limiting usage was aptly named “the ecological fallacy” (21).
This fallacy is based upon a simpliﬁed view of evolution in which ﬁtness gains due
to antibiotic resistance are offset by ﬁtness costs to bearers of resistance phenotypes
due to reduced performance in other aspects of their biology, i.e., trade-offs. The ﬂaw
in this reasoning is the assumption that the absence of an antibiotic from the environment has the same level of impact as, but opposite effect of, its presence. We have
learned that reversion to sensitivity is neither an immediate nor necessary outcome of
selection simply because a resistant pathogen is no longer in an antibiotic-laden environment (24, 25). The reasons for this relate to the lasting impact of antibiotic treatment upon microbes as well as changes at the genetic level that reconﬁgure the ﬁtness
landscape for resistant populations and make reversion less likely (26–28). In essence,
the presence of clinical concentrations of antibiotics more strongly selects for resistance than the absence of antibiotics selects for reversion to antibiotic sensitivity.
THE ENVIRONMENTAL RESISTOME
Microbes are among the oldest extant organisms and during their billions of years
of existence have come into close contact with toxic molecules of all types. Microbial
genomics has provided a wealth of data indicating that most bacterial genomes have
November/December 2021 Volume 12 Issue 6 e01966-21
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BOX 1: ANTIBIOTIC RESISTANCE IN THE PREANTIBIOTIC ERA
Bacteria are incredibly resilient organisms. Microbiology labs around the world
regularly store bacterial samples for the long term by freezing a prepared sample in
ultracold freezers. With a little care, these frozen bacterial samples can be viable again
after thawing; in essence, the cells “wake up” and get back to growing and reproducing.
In times past, however, such storage techniques were not available to microbiologists.
So how did these scientists store bacterial samples they collected? Many would store a
collected sample in a stab tube. Stab tubes are sterile test tubes that have tightly ﬁtting
caps. These tubes can be ﬁlled with sterile nutrient agar, which solidiﬁes at room
temperature. The bacterial sample can then be stabbed into the agar and the test tube
sealed and stored in the dark.
Storage in this manner regularly preserves bacteria for two to several years but in
some cases even longer. From 1917 to 1954, bacteriologist E. G. D. Murray collected
several hundred bacterial samples in this way. Because of his skilled sterile technique
and careful practices, the Murray collection is still available for research and study. Most
of the Murray collection predates the use of antibiotics and has served as an important
research tool for understanding the types and levels of antibiotic resistance that existed
in the preantibiotic era. Murray’s collection showed that low levels of antibiotic
resistance were not uncommon and that plasmids containing antibiotic resistance genes
predate clinical use of antibiotics. The Murray collection is now part of the National
Collection of Type Cultures (NCTC), one of four major collections that make up Public
Health England and supports researchers and clinicians worldwide.

genes that allow them to become resistant to one or more antibiotics. These data have
led to the development of the concept of an “antibiotic resistome,” which includes all
antibiotic resistance genes (ARGs) and their precursors in both pathogenic and nonpathogenic bacteria (29, 30).
Notably, ARGs exist in all ecological niches that harbor microbial communities.
These ﬁndings reinforce the essential role that antibiotics and other toxic substances
have played in bacterial evolution and strongly suggest that resistance to antibiotics
has coevolved along with antibiotic biosynthesis (reviewed in reference 31). The metagenomic analysis of ancient DNA shows clearly that antibiotic resistance is a natural
mechanism that predates the use of antibiotics as therapeutic drugs (32). Soil bacteria
play an essential role in the production of antibiotics and provide deep insight into the
capacity to inactivate them. For instance, the genome of soil actinomycetes contains
more than 20 biosynthetic gene clusters for diverse bioactive compounds and ARGs
(33). In addition, there are soil bacteria that can use antibiotics as their sole carbon
source (34). A deep understanding of the functional role of both antibiotic biosynthesis
and ARGs in the environment can shed light onto how to address the future use of
antibiotics to ﬁght bacterial infections.
NATURAL RESISTANCE
Retrospective investigations into the existence of resistance in the time before the
introduction of penicillin (the preantibiotic era [Box 1]) indicate that ARGs were not
only present but also common in a wide range of bacterial species (35), particularly on
plasmids (36, 37). While the number of such preantibiotic-era studies is limited, we see
that resistance to naturally occurring antibiotics was common (38), with more than
one ARG existing for natural antibiotics such as penicillin (35). The number and diversity of ARGs in the preantibiotic era are much greater than expected, and plasmids carrying these genes have long been horizontally transferred within and between species
(35). These data suggest that antibiotic resistance has been in existence for as long as
antibiotics themselves (2). Why then did widespread antibiotic resistance never arise
November/December 2021 Volume 12 Issue 6 e01966-21
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BOX 2: PK/PD BASICS
Antibiotics are known to work in the lab because we can measure things such as
minimum inhibitory concentration (MIC) or the size of the zone of inhibition. But how do
we go about determining what the dosage should be in the clinic? The answer to this
question is pharmacokinetics and pharmacodynamics (PK/PD). In order to effectively
and consistently kill a pathogen within a patient undergoing treatment, the
concentration of the antibiotic must remain at or above the MIC for the pathogen.
However, the concentration does not remain constant after dosing; it quickly climbs to a
peak, known as the maximum concentration in serum (Cmax), and then drops off over
some amount of time. A second dose is then needed to bring the concentration back up
again before it falls below the speciﬁed MIC for the pathogen.
Plotting the serum concentration of the antibiotic over time produces a graph with a
peak at Cmax, along with other information relevant to PK/PD analyses. For instance, the
area under the concentration-time curve (AUC) for a speciﬁed time (usually 24 h) is a
measure of how efﬁcient each dose of antibiotic can be. Then, by normalizing Cmax and
AUC24 by MIC, a PK/PD “index” can be generated for a speciﬁc antibiotic-pathogen
pairing.

and sweep to ﬁxation over the millions of years of consistent use by microbes, though
it so reliably and irreversibly evolves in treatment for modern pathogens?
HOW ARE ANTIBIOTICS USED IN NATURE?
In nature, antibiotics are employed in a very different way than they are in clinical
treatment. Most glaringly, antibiotics are not produced in such high concentrations, for
such long durations, or at such large scales. In the clinic, antibiotics are used to kill all
susceptible bacteria; any outside consequences of that use are ancillary. As such, the
differences in the application of antibiotics between microbes and the clinic should be
carefully considered, as these differences suggest that their effects may also differ.
CONCENTRATION, DURATION, AND SCALE
Clinical use of antibiotics in humans is centered upon concentrated delivery of the
compound over time. This usage directly ties concentration and duration together in a
fundamental way. Clinically effective doses of antibiotics are identiﬁed using pharmacokinetics and pharmacodynamics (PK/PD [Box 2]). Dosing of an antibiotic to cure an
infectious disease is a determined function of the peak concentration of antibiotic (a
proxy of bacterium-killing power) and the efﬁcacy of a delivered dose over time, usually 24 h (a proxy measure of chemical stamina in situ) (39). Put simply, the measured
ability of a single dose of an antibiotic to kill bacteria and persist at detectable concentrations is optimized by PK/PD for clinical use against a bacterial strain of speciﬁed susceptibility. If low-level resistance is found in a strain, higher peak and residual concentrations over the speciﬁed time are used (39).
PK/PD curves must be determined for humans and animals, since biologically active
hosts will metabolize and excrete the antibiotic (40). This degradation reduces the total
drug present over time, with the entire host environment capable of metabolizing the
drug. Contrast this with natural environments where antibiotic concentrations will be
more variable over time. Clearly there will be no PK/PD-like optimization and, in an
environment such as soil, metabolic degradation will be more transient than would be
the case in animal tissue. As a result, antibiotics in natural environments, such as soil,
may linger for much longer periods of time than in clinical use. Experimental data support this conclusion (41), showing that antibiotics in soil, water, and even plants seem
to persist over longer periods of time before they are degraded by biotic and abiotic
November/December 2021 Volume 12 Issue 6 e01966-21

mbio.asm.org 5

Minireview

®

reactions, mostly by microbial populations (42). But the ability of microbes to degrade
environmental antibiotics suggests that this process is heavily dependent upon the type
and size of microbial communities present, as well as abiotic conditions such as temperature, moisture, and pH (43). Given the reliance on such diverse (and uncontrolled) variables in the environment, antibiotic degradation is decidedly slow and heterogeneous.
The most likely result is longer antibiotic residence time in the environment.
Concentration, however, is a different issue. There are no consistent data on natural
antibiotic concentrations in the environment (reviewed in reference 42), but concentrations are reasonably suspected to be much lower than those used in the clinic (41,
44). For a compound to be functional as an antibiotic, i.e., either bactericidal or bacteriostatic, concentrations in nature must meet or exceed the MIC for the target species/
strain. Often, the MIC can be extremely low (,0.016 mg/L or ,0.016 ng/m L) (45). Such
concentrations should be achievable in naturally growing populations, although likely
over only limited distances. The result is that a single microbe can produce a small
amount of an antimicrobial compound that raises the concentrations to or above MICs
in the microliter-sized space around that particular cell. As many cells within the population produce the antibiotic, the concentration in the volumetric space around that
population increases.
Nonetheless, concentrations of antibiotics in naturally occurring populations are not
likely to approach even the same order of magnitude as in the clinic (46). Consider streptomycin: in patients with tuberculosis, target serum concentrations are often about
40 m g/mL (47), or 160 higher than the measured MIC for Mycobacterium tuberculosis
(48) (and 2,500 higher than an MIC of 0.016 mg/L). This difference in concentration represents a drastic change in the magnitude of selection, with all low-level-resistant
mutants being impacted in the same way and to the same degree as completely sensitive
wild-type clones.
The conclusion is that concentrations of naturally occurring antibiotic compounds,
and their effects, are orders of magnitude lower than those used in the clinic. In addition, the time in which antibiotics remain in natural environments is different than in
human patients (43). Pharmacodynamics not only optimizes peak concentrations but
also sets lower limits below which serum concentration should not fall. This lower limit
is often associated with the measured MIC for the pathogen. Any time spent below
this level is implicated in selection for resistance mutations, such as in the mutant
selection window hypothesis (49, 50). Therefore, from an evolutionary perspective, the
way we use antibiotics is central to the current problem of antibiotic resistance and
may be crucial to understanding how microbes have been able to employ antibiotics
over long periods. In the natural situation described, a concentration gradient exists in
space, with higher concentrations closer to the source and lower concentrations further away (Fig. 2). In the clinical picture, the concentration gradient exists in time, with
values during treatment in a constant, cyclical, and controlled ﬂux. In addition, antibiotic concentrations are roughly the same everywhere within the host at any given
time. The important distinction between these two lies in the possible responses: a
physical gradient can be tolerated through movement, perhaps even small ones. In
contrast, a temporal ﬂux, particularly at the concentrations considered, becomes an
existential condition, necessarily impacting the ability to survive, and with it, the
strength and direction of selection.
Similarly, it has been shown that combinations of antibiotics can enhance or diminish bacteriostatic or bactericidal effects (44, 51, 52), suggesting that clinical-level concentrations are not the only way of ensuring population-level effects upon microbes.
This range of combinatorial effects adds depth to the number of possible outcomes in
a localized environment as synergistic effects of antibiotics can both lower the probability of evolving resistance and expand the mutant selection window via antagonistic
interactions.
The last of our immediate considerations is that of scale. The limited concentration
and unknown duration of antibiotic compounds in natural environments contrast with
November/December 2021 Volume 12 Issue 6 e01966-21
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FIG 2 Effect of antibiotics upon microbial community interactions. In nature, antibiotics can have signiﬁcant
impacts upon interactions between species and strains of microbes. Rather than acting solely as a microbial
weapon of warfare, we know that antibiotics can also function as signaling molecules and transcriptional
modiﬁers. Antibiotic compounds can also create opportunities for community mutualisms with strains both
resistant and sensitive, depending upon the context of the interaction. This suggests that antibiotics can play
important and complex roles in community assembly and diversity and further implies the importance of
paired production and resistance genes in microbial ecology.

the consistently high concentrations called for by PK/PD. Additionally, the impact of
human use of antibiotics is global, in all senses of the word.
Within patients, antibiotics are distributed by design throughout the body. Ease of
infection site delivery has always been a key advantage of antibiotics. Patients are
treated with antibiotics orally, intravenously, rectally, or via injection, with circulatory
systems facilitating transport to infected areas. This effortlessness is due in large part
to the small size of antibiotic molecules and the fact that they have little cross-reactivity with molecules outside the target species (5). Contrast this with the complications
of infection site delivery associated with other approaches, such as phage therapy (53,
54). The combination of the ease of delivery with the widespread use of broad-spectrum antibiotics to treat large groups of suspected (but not necessarily identiﬁed)
pathogens results in the within-patient ubiquity of antibiotics upon which we have
come to rely.
On a larger scale, since 1940, antibiotics have become an omnipresent pollutant in
environments of all types (55). Even in places largely untouched by humans, we can
ﬁnd antibiotic compounds and, with them, ARGs (56–59). In recent years, we have
learned that even low levels of antibiotic pollution select for high levels of resistance
(60–62). Additionally, regardless of the biome or their ability to clear pollutants,
humanity’s worldwide industrial-level use of antibiotics has resulted in a steady stream
of antibiotics into the environment, without ever allowing natural systems to return to
baseline levels (63).
November/December 2021 Volume 12 Issue 6 e01966-21
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The result of humanity’s overproduction and misuse of antibiotics, including their
massive presence in agriculture and animal husbandry (64–66), is the transformation of
a natural product used in limited scope within microbial communities into a biological
weapon of mass destruction dispatched against microbial communities of all types in
all places. This abuse is on the same scale as nuclear weapons testing, another misused
mid-twentieth century technology (67). Although the expected duration of antibiotic
contamination is thought to be signiﬁcantly shorter than that of nuclear fallout (68),
the long-term impact upon microbial communities and the genetic changes necessarily imposed by selection for resistance through contamination of the environment is
beyond calculation. (Interestingly, although the timeline of nuclear fallout and its
impact is much longer than that of antibiotic pollution in the environment, antibiotic
pollution has already lasted longer in terms of generations for microbes. Radionuclides
resulting from test explosions, such as plutonium-239 [half-life, 24,000 years], degrade
on a scale of approximately 1,000 human generations. Even if we require several halflives to have passed in order to accept a lower nuclear pollution level, that time is still
dwarfed by the number of microbial generations that have passed since the industrial
production of antibiotics started in 1942.)
SIGNALING
If the concentration, duration, and scale of antibiotic use in nature are so vastly different from clinical use, the question of what need antibiotics evolved to meet remains.
What is the role of antibiotics in natural environments? Potential answers to this question are few, but one hypothesis that has gained considerable support is that antibiotics function as a signaling molecules in microbial environments (69–71). The observation that low concentrations of antibiotic compounds can act as transcriptional
regulators has become integral to our understanding of interspeciﬁc dynamics in natural microbial communities (72, 73). The transcriptional changes induced by antibiotic
compounds range widely from species to species and compound to compound; however, many of the genes upregulated are implicated in stress response or bioﬁlm-associated phenotypes, suggesting that the use of antibiotics in nature differs from their
presumed role as weapons of microbial warfare. In fact, we argue that this presumption cannot be correct.
Consider how antibiotics are dispersed through space in a natural medium, such as
soil. Microbial cells produce and excrete the antibiotic into the space around them. The
concentration is highest at the source and drops with distance from the producer cells.
The result is a zone of inhibition, the phenomenon Fleming ﬁrst observed in 1928. A
standardized paper disk or Kirby-Bauer test (74) is based upon the principle that the
outer circumference of the zone of inhibition is directly related to the MIC for the bacterial strain tested, meaning that at the outer edge, the concentration of the antibiotic
being tested is high enough to stop growth. However, the diffusion of the antibiotic can
reasonably be expected to continue past the outer ring of the inhibition zone (disregarding any metabolic inactivation) and should continue to decrease over space, potentially
affecting transcription in the bacterial cells present in this space (75). Contrast this with
the PK/PD approach, where the goal is to maintain high serum concentrations in the
entire volume over a speciﬁed time. Hormesis and the totality of antibiotic effects upon
microbial populations are still not well understood (76). Combinations of antibiotics can
also shift the effects of antibiotic compounds in an environment (44), suggesting that
the lower concentrations found in nature might have oversized effects upon bacterial
populations based on the totality of compounds present. Such synergistic or antagonistic effects may also inform hypotheses as to why microbes produce and excrete both
bacteriostatic and bactericidal compounds, as well as offering a hypothesis underlying
observations of antagonism between these different types of compounds, particularly at
microbial scales (77).
In addition, the range of natural environments in animal hosts for microbes is large.
Consider, for example, the different environments possible for “gut microbiomes.” In
November/December 2021 Volume 12 Issue 6 e01966-21
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each of those, different bacterial communities with speciﬁc functional requirements
will coexist. Furthermore, the impact of antibiotics on such communities (and their residual inﬂuence on host health) are vital to a complete understanding of the effect of
antibiotics and resistance in natural microbial environments (78). Clearly, the use of
antibiotics in natural environments has more to teach us about how and why these
compounds have been in use for eons, forcing us to re-evaluate our assumption that
the sole purpose of antibiotics lies in antagonism.
REINTERPRETING ANTIBIOTICS WITH NATURE AS OUR ROSETTA STONE
Clinical use of antibiotics is rooted in the assumption that species producing a particular antibiotic do so for the purposes of directly competing against other species or
strains in the natural environment. This presumption is the same as that which underlies antibiotic use by humans; antibiotics are armaments of antagonism, produced by
one microbe and meant to hinder another.
Interestingly, humans depart from this supposition more than we adhere to it: clinical therapeutics is not the largest use of antibiotics and has not been for some time. In
the 1940s, it was observed that livestock more efﬁciently achieved market size when
given low doses of antibiotics (79, 80). While hypotheses for this observation exist (81),
a complete explanation has not yet been deciphered. Nonetheless, we continue to use
most industrially produced antibiotics not for microbial antagonism per se but rather
for faster animal growth, without regard for the mode of action or its consequences.
Given humanity’s incomplete and inconsistent consideration of antibiotics, their
application, and their purpose, a more complete analysis of their use under conditions
shaped by evolutionary and ecological forces is warranted, particularly given the long
success microbes have had using antibiotics and, perhaps more importantly, managing
antibiotic resistance.
First and foremost, we note that, in nature, synthesis of and resistance to antibiotics
are intimately connected. Studies of naturally occurring resistance indicate that an
ARG is often linked with the genes involved in biosynthesis of that antibiotic (82). This
association is conﬁrmed in samples representing preantibiotic-era strains as well as
those from pristine environments, with many of the antibiotic-resistance pairs encoded
in phylogenetically related groups (38). The consistent pairing of antibiotic production
with ARGs within monophyletic groups, coupled with such production-resistance pairings on mobile plasmids (35), strongly suggests that this connection signals a longstanding fundamental characteristic of antibiotic use in nature.
Phylogenetic ties between strains and groups are also supported by ecological
interactions between and within these groups. More often than expected by a null
model, microbial communities are made up of phylogenetically related interacting species (83, 84). The hypothesis underlying this observation is that abiotic variables in the
environment ﬁlter community members and more closely related species are more
likely to have similar niches (84, 85). We propose another possible hypothesis for this
observation: community assembly is governed by biotic or, perhaps more properly, antibiotic ﬁlters as much as abiotic ﬁlters. This hypothesis explains the phylogenetic clustering observed in microbial communities across a large array of environments, as well
as the consistency of groupings at the family taxonomic level observed in communities
(83). Additionally, the existence of such mutualisms would also provide an explanation
for the observations of antibiotic resistance arising as an emergent phenomenon
within some communities as a result of cooperative action rather than from the biochemical processes within single cells (86).
As communities grow, distinct pairings that represent symbiotic interactions are often vital. It is beneﬁcial for a species present to ﬁlter the pool of possible neighbors
with which they will interact so as to increase the likelihood that a beneﬁcial partner
will be present, particularly when limited carbon resources are likely to be utilized by
more than one member of the community (87). By producing and secreting a given antibiotic into the space around the producer’s position, a species may not be so much
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trying to impair competitors as to reserve space for proven partners. Experimental evidence of community construction based upon interactions in which antibiotics play a
role has been observed (88, 89). Neighbors thus selected will need to be antibiotic resistant, which may also be more probable if they are also phylogenetically related to
the producer. In addition, because of the pairing of antibiotic production genes with
ARGs, the resistant neighbor is also more likely to be able to produce the same antibiotic compound, thereby reinforcing the screening effect and reserving even more
space for the mutualistic pair to then grow into and/or control. Such a dynamic would
indicate that resistance is precisely the mechanism that makes antibiotics valuable in
natural microbial communities. Further, multimember community action is implicated
as combinations of antibiotic-classes present can enhance or antagonize the effects of
an antibiotic overall (52), leading to additional community-level ﬁltering capacity.
The implication that natural antibiotic production and resistance should be intimately tied together can be contrasted with the presumption that antibiotics are a
weapon of microbial warfare. In the combat framework, antibiotic production is beneﬁcial, with the ability to produce more being better (akin to the PK/PD approach). This
dynamic implies the strong potential for an evolutionary arms race. However, this system seems never to have dwelled in the realm of the red queen: hyperproducers (on
the scale of clinical concentrations) are not known, nor are high levels of resistance.
The strain of P. chrysogenum that Mary Hunt isolated from a rotting cantaloupe was a
hyperproducer of penicillin, but artiﬁcial selection and X-ray mutagenesis experiments
yielded even higher-producing mutants (90), suggesting that such a mutational path
was possible via one or a few mutational steps but not likely to have ever been beneﬁcial to ﬁtness.
In addition, investigations into the evolution and long-term application of antibiotics as weapons of microbial warfare suggest that the microbial armory is large and
diverse (91) but that evolutionary strategies that employ competition and antagonism
ultimately need to be tightly controlled (92). Control is ultimately both costly and complex (92), particularly when eukaryotes are also considered (93). The cost of control
mechanisms, along with their near-ubiquity across microbial species (92), suggest that
a large-scale evolutionary arms race(s) was limited, even though the number and types
of microbial “weapons” continued to diversify. A slightly different approach, and one
that is in line with evolutionary game theory (94), is that even limited cooperation can
be less costly over the number of interactions likely as well as over the evolutionary
time scales involved. Consider that clinically relevant antibiotic resistance of the kind
common today is known to be costly to ﬁtness overall, making both sides of this evolutionary war game losing strategies without a consistent and strong offsetting force.
Any breakdown of such a compensating tension would likely lead to antibiotics rapidly
losing all potential beneﬁt and being selected against by natural selection, followed by
costly ARGs (although this argument runs dangerously close to replaying the ecological fallacy). Pairing these phenotypes, however, creates a balanced approach that can
be maintained via selection by the constant need for community assembly across
many environments over vast evolutionary timescales.
Even strains that are not resistant to a particular antibiotic may be inﬂuenced by
low concentrations of the compound through transcriptional changes and gene regulation (95, 96). Genes that are transcriptionally impacted could possibly make the species more likely to cooperate with the antibiotic producer or, alternatively, less likely to
invade the producer’s space (edge-specialist bacteria?). Such suppositions are amenable to experimental inquiry and offer one potential line of hypothesis testing and/or
development.
This cooperative effect would presumably be greatest just beyond the outer edge
of a zone of inhibition, where concentrations are lower, suggesting a kind of secret
“friend or foe?” inquiry being put to a potential neighbor by the producer prior to any
direct interaction. Similar systems are known to exist in quorum sensing feedbacks in
species such as Clostridioides (formerly Clostridium) difﬁcile (97), suggesting that
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nonconstitutive phenotypes can be induced based upon biointeractions with adjoining bacterial cells. Given the metabolic and ﬁtness costs associated with antibiotic production, it is not surprising that researchers are also ﬁnding antibiotic synthesis linked
to quorum sensing in cocultures (98, 99), particularly as a mechanism to limit social
cheaters (100), suggesting that a main outcome of these interactions is related to community building and stability (101).
This “secret society” hypothesis, where known members are trusted, new members
undergo hazing-like phenotype acquisition, and potential newcomers are continuously
recruited, also provides a potential explanation for why ARGs in the clinic are often
associated with plasmids. Preantibiotic-era plasmids often maintained a producer-resistance pairing. This may have been beneﬁcial in increasing the likelihood of a pair of
successful community members becoming neighbors again in another community
even if they are not phylogenetically related. The probability of a mutualistic association could be increased in the future by the sharing of a plasmid by a producer: in
essence, an initiation ritual. A recent study showed increased probability of plasmid
persistence with increasing numbers of strains in a community (102). A similar system
exists in colicinogenic plasmids in certain strains of Escherichia coli, where the colicin
operon, containing a colicin-encoding gene (cxa), is bundled with the immunityencoding gene (cxi or imX) (103). Plasmid transfer is also affected by antibiotic concentration, with the makeup and structure of microbial communities inﬂuencing what the
target recipients of plasmids may be (104), suggesting again that antibiotics have long
been tied to the structure and makeup of microbial communities.
If the secret society system was a dominant selective force in evolving and maintaining antibiotics in the preantibiotic era, then changes in the magnitude, frequency,
and diversity of antibiotics after 1940 would likely have caused a consequent shift
away from a production-resistance balance in favor of a resistance-dominated evolutionary strategy. We observe just such a signal when we compare the levels of resistance in preantibiotic era collections to modern circulating strains of bacteria (105). We
also observe such co-option of existing plasmids in the environment (106). Such evidence compels us to consider the possibility that the propensity to donate a plasmid
containing a production-resistance pair may have regularly been co-opted by bacteria
after the dawn of the antibiotic age, driven by selection, as a measure to survive clinical
treatment with high concentrations of industrially produced antibiotic compounds.
GHOSTS OF RESISTOMES PAST
One potential concern inherent in a secret society system is that past violations in
which the pairing was broken would likely already have become ﬁxed within the relevant population(s). This leads to consideration of what potential signatures of the
paired system might exist beyond those already mentioned.
The question of concern is whether broken pairings in the past could have led to ﬁxation of ARGs, which would in turn lead to the eventual loss of synthesis genes for those
speciﬁc natural antibiotics. If antibiotics were used in eons past not in a paired way but
rather as a way to kill competitors, as has long been the presumption, then resistance to
that antibiotic compound would be highly beneﬁcial to ﬁtness. The frequency of resistance carriers would increase and become ﬁxed over time, rendering the antibiotic useless.
The ability to synthesize the antibiotic would (presumably) be lost via selection over time.
How, then, can we put forward the secret society hypothesis without being able to know
if such a simple series of events happened in the distant past?
One possible approach would be to look for echoes of selection from long ago pairings compared to the natural antibiotic compounds present today. More precisely, we
can look at the half-life of natural antibiotics in their relevant environments to understand how quickly they naturally degrade and use those data to inform a null hypothesis. There are three likely scenarios: extant natural antibiotics could have a longer halflife than other compounds, such as signaling molecules; they could have a shorter
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half-life; or they could have one that is about the same as that of other synthesized
extracellular compounds.
Should natural antibiotics have a comparable half-life, not much new information can
be gained. If they have a shorter half-life in the environment than similar extracellular
molecules, that would imply that natural antibiotics are incapable of building up in the
natural environment, rendering the likelihood of runaway selection for resistance low.
However, if the half-life of natural antibiotics in the environment is long, then selection for resistance to the accumulated concentration of these compounds becomes
more likely. If this happened long ago, we would have lost any signal, because the resistance alleles would have become ﬁxed perhaps before we even knew of microbes’
existence. Therefore, we would expect that natural antibiotics have a shorter half-life
than most other naturally produced extracellular compounds, since we can still ﬁnd
such a diversity of them produced in microbial communities. While not a deﬁnitive
test, such an approach provides for some baseline experimental inquiry.
CONCLUSIONS AND FUTURE PROSPECTS
To have any hope of countering the rise in antibiotic-resistant infections, we will
need to better understand the source, impact, and implications of the problem. While
concern over infection rates is a biomedical matter, resistance is the result of evolutionary processes. Here, we argue that as a precursor to developing effective mitigation
strategies, we need to expand consideration beyond either biomedicine or evolutionary biology and include the vast ecological dimension.
We began by asking why antibiotics exist at all, given that resistance to clinical drugs
has so reliably evolved shortly after the introduction of every new class of antibiotics over
the past 80 years. Antibiotics are not new; they are older than the human species. Yet,
within a single human lifetime, many clinical antibiotics have been rendered ineffective.
Within another lifetime, antibiotic resistance may become the scourge of our time. To
understand this sea change, we look to the biological history of these secondary microbial metabolites for clues as to how their use might be preserved.
Most profound among the differences between the historic use by nature of antibiotics and their current therapeutic purpose is the divorce of antibiotic use from any
counterbalanced resistance. Separating these ecologically conjoined twins and removing the context and countercontext put their trajectories on different, and ultimately
dangerous, paths. The concentration, duration, and scale of human use created a
potent artiﬁcial selection for antibiotic resistance to unnaturally high levels and frequencies. Evolution to resistance under clinical antibiotic conditions is, quite literally, a
mandatory survival strategy for microbes.
Data collected over decades suggest that antibiotic production phenotypes have
largely been paired with complementary antibiotic resistance phenotypes (2, 36, 37,
91). A similar pairing is found in other microbial toxin systems, such as in colicins (103).
Nature’s signal in this regard seems clear: producing an antibiotic is not very meaningful without also being resistant. Horizontal gene transfer systems, particularly plasmids,
reinforce this conclusion, but the number and type of such plasmids suggest that antibiotics play a larger role than just a weapon of war among microbes. We suggest that
this larger role is one of mutualistic cooperation, particularly important in establishing
and maintaining microbial communities.
Beneﬁcial interactions in one community can become more likely in other communities if the interactors are both present in the new community. But we still do not understand all the ways in which cooperative interactions begin (107). Antibiotic use as
described here may offer additional insight into this area. Novel, beneﬁcial interactions
can be reinforced and even reciprocated through production of an antibiotic by one or
both participants. In addition, the exchange of antibiotic production and resistance genes
could cement a relationship for future interactions. The importance of such mutualisms
may be intensiﬁed given the structured spatial makeup of microbial communities, such
as in bioﬁlms, as well as the number and types of producers present (44, 51).
November/December 2021 Volume 12 Issue 6 e01966-21

mbio.asm.org 12

®

Minireview

This pairing of production and resistance levels may have been the main means of
maintenance over millions of generations. Neither production amounts nor resistance
levels experienced directional selection pressure to increase or decrease, since there
would be signiﬁcant ﬁtness costs without any beneﬁt gained. In addition, if a given
cooperation was beneﬁcial to the community, that interaction would be selected for
under the conditions experienced. In other words, there would exist selection for a
maintained balance between antibiotic production and resistance.
Of course, the implication is that humans broke this microbial social contract by coopting antibiotics under the presumption that they were an underutilized tool and
transforming them into a biological weapon of mass destruction. In doing so, we created a potent selection for higher and higher resistance levels; losing the ability to control or manipulate it was inevitable, if not foreseen.
We have put forward the hypothesis that antibiotic resistance is not an evolutionary
reaction to antibiotic warfare but rather a cocomponent of a preferred assembly mechanism for microbial communities. This hypothesis can be investigated experimentally.
Such a series of experiments would continue to shine light not only on the mechanism
and role of antibiotics in natural systems in the preantibiotic era but also on their importance in an ecological context. Finally, by understanding how the pairing of antibiotic production with resistance can achieve and maintain a balance, we will have
developed the potential for mitigation strategies that may impact human health for
lifetimes to come.
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